The purpose of this pilot study is to evaluate the safety and efficacy of a novel drug, BG34-200, to stimulate the body’s immune system to recognize and attack cancer cells in dogs with malignant melanoma, mammary carcinoma, and other high-grade soft tissue sarcomas. Other solid tumors may qualify, as well.

ELIGIBILIGY:

• Dogs weighing 15 kg (33 pounds) or more
• Histologic or cytologic confirmation of a solid tumor malignancy such as:
  • Malignant melanoma
  • Mammary carcinoma
  • High grade soft tissue sarcoma
  • Osteosarcoma (if amenable to repeat biopsies)
• Tumor must be 2 cm or larger

Prior treatments are permissible as long as there is a measureable tumor present. Anticipated study duration consists of 6-7 weekly visits. This includes: screening visit(s), four treatment visits, and one final follow-up visit. All appointments require the ability to travel to the University of Pennsylvania Veterinary Hospital, in Philadelphia, PA.

BENEFITS:

• All study specific visits will be covered by the study after enrollment has begun.
• Capped hospital credit applied to record for future treatments (such as surgical excision, chemotherapy, radiation therapy, etc.)

CONTACT: If interested, please contact PennVet’s Clinical Investigations Department (VCIC) by phone: 215.573.0302 or email: vcic@vet.upenn.edu